Abstract
(Int J Obstet Anesth. 2019;39:22–28) Although epidural analgesia remains the preferred method of labor analgesia, remifentanil patient-controlled analgesia (PCA) is a popular alternative due to its quick onset and rapid metabolic properties. Remifentanil PCA has been used in Europe for several years, but its safety has been questioned by some due to concerns about potential serious side effects, such as respiratory depression for both mother and neonate. Since the current rate of serious adverse events (SAEs) connected to remifentanil PCA use during labor is unknown, the current investigators conducted this study to measure the frequency of SAEs, as well as examine the clinical circumstances associated with SAEs and the management of those events.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
